Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?

Cardiovascular Diabetology

Volumn 7, Issue , 2008, Pages

  Gani, Osman A B S M ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BEZAFIBRATE; BM 298585; CLOFIBRATE; DOCOSAHEXAENOIC ACID; FATTY ACID DERIVATIVE; FENOFIBRATE; FISH OIL; GLITAZONE DERIVATIVE; GW 0072; ICOSAPENTAENOIC ACID; MURAGLITAZAR; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TELMISARTAN; TESAGLITAZAR; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DRUG DERIVATIVE; LIGAND;

ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG STRUCTURE; EDEMA; GLUCOSE HOMEOSTASIS; HEART INFARCTION; HUMAN; LIGAND BINDING; LIPID METABOLISM; METABOLIC DISORDER; NEOPLASM; SIDE EFFECT; STRUCTURE ANALYSIS; TRANSACTIVATION; WEIGHT GAIN; X RAY CRYSTALLOGRAPHY; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DOCOSAHEXAENOIC ACIDS; DRUG DESIGN; EICOSAPENTAENOIC ACID; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PPAR ALPHA; PPAR GAMMA; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS);

EID: 42449125303     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-7-6     Document Type: Article

References (45)

1. Willson TM Brown PJ Sternbach DD Henke BR The PPARs: From orphan receptors to drug discovery J Med Chem 2000, 43(4):527-550. 10.1021/ jm990554g 10691680
2. Henke BR Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes J Med Chem 2004, 47(17):4118-4127. 10.1021/jm030631e 15293980
3. Barish GD Narkar VA Evans RM PPAR delta: A dagger in the heart of the metabolic syndrome J Clin Invest 2006, 116(3):590-597. 1386117 16511591 10.1172/JCI27955
4. Kliewer SA Sundseth SS Jones SA Brown PJ Wisely GB Koble CS Devchand P Wahli W Willson TM Lenhard JM Lehmann JM Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma Proc Natl Acad Sci U S A 1997, 94(9):4318-4323. 20720 9113987 10.1073/pnas.94.9.4318
5. Krey G Braissant O L'Horset F Kalkhoven E Perroud M Parker MG Wahli W Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay Mol Endocrinol 1997, 11(6):779-791. 10.1210/ me.11.6.779 9171241
6. Nesto RW Bell D Bonow RO Fonseca V Grundy SM Horton ES Le Winter M Porte D Semenkovich CF Smith S Young LH Kahn R Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003 Circulation 2003, 108(23):2941-2948. 10.1161/ 01.CIR.0000103683.99399.7E 14662691
7. Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007, 356(24):2457-2471. 10.1056/NEJMoa072761 17517853
8. Fievet C Fruchart JC Staels B PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome Curr Opin Pharmacol 2006, 6(6):606-614. 10.1016/j.coph.2006.06.009 16973418
9. Ferrara P Gohlke H Price DJ Klebe G Brooks CL 3rd Assessing scoring functions for protein-ligand interactions J Med Chem 2004, 47(12):3032-3047. 10.1021/jm030489h 15163185
10. Peters JM Aoyama T Burns AM Gonzalez FJ Bezafibrate is a dual ligand for PPARalpha and PPARbeta: Studies using null mice Biochim Biophys Acta 2003, 1632(1-3):80-89. 12782154
11. Tenenbaum A Motro M Fisman EZ Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: The bezafibrate lessons Cardiovasc Diabetol 2005, 4:14. 1236941 16168052 10.1186/ 1475-2840-4-14
12. Neschen S Morino K Dong J Wang-Fischer Y Cline GW Romanelli AJ Rossbacher JC Moore IK Regittnig W Munoz DS Kim JH Shulman GI n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner Diabetes 2007, 56(4):1034-1041. 10.2337/db06-1206 17251275
13. von Schacky C n-3 PUFA in CVD: Influence of cytokine polymorphism Proc Nutr Soc 2007, 66(2):166-170. 10.1017/S0029665107005411 17466099
14. Heim M Johnson J Boess F Bendik I Weber P Hunziker W Fluhmann B Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes FASEB J 2002, 16(7):718-720. 11923221
15. Forman BM Tontonoz P Chen J Brun RP Spiegelman BM Evans RM 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma Cell 1995, 83(5):803-812. 10.1016/ 0092-8674(95)90193-0 8521497
16. Hasegawa H Yamada Y Komiyama K Hayashi M Ishibashi M Sunazuka T Izuhara T Sugahara K Tsuruda K Masuda M Takasu N Tsukasaki K Tomonaga M Kamihira S A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Delta 12, 14 prostaglandin J2 production Blood 2007, 110(5):1664-1674. 10.1182/blood-2007-01-068981 17551094
17. Evans RM Barish GD Wang YX PPARs and the complex journey to obesity Nat Med 2004, 10(4):355-361. 10.1038/nm1025 15057233
18. Vu-Dac N Schoonjans K Kosykh V Dallongeville J Fruchart JC Staels B Auwerx J Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor J Clin Invest 1995, 96(2):741-750. 185258 7635967 10.1172/JCI118118
19. Rosen ED Walkey CJ Puigserver P Spiegelman BM Transcriptional regulation of adipogenesis Genes Dev 2000, 14(11):1293-1307. 10837022
20. Wang YX Lee CH Tiep S Yu RT Ham J Kang H Evans RM Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity Cell 2003, 113(2):159-170. 10.1016/ S0092-8674(03)00269-1 12705865
21. Mangelsdorf DJ Thummel C Beato M Herrlich P Schutz G Umesono K Blumberg B Kastner P Mark M Chambon P Evans RM The nuclear receptor superfamily: the second decade Cell 1995, 83(6):835-839. 10.1016/0092-8674(95)90199-X 8521507
22. Keller H Dreyer C Medin J Mahfoudi A Ozato K Wahli W Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers Proc Natl Acad Sci U S A 1993, 90(6):2160-2164. 46045 8384714 10.1073/ pnas.90.6.2160
23. Zoete V Grosdidier A Michielin O Peroxisome proliferator-activated receptor structures: Ligand specificity, molecular switch and interactions with regulators Biochim Biophys Acta 2007, 17317294
24. Glass CK Rosenfeld MG The coregulator exchange in transcriptional functions of nuclear receptors Genes Dev 2000, 14(2):121-141. 10652267
25. Connor WE Importance of n-3 fatty acids in health and disease Am J Clin Nutr 2000, 71(1 Suppl):171S-5S. 10617967
26. Sheu SH Kaya T Waxman DJ Vajda S Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping Biochemistry (Mosc) 2005, 44(4):1193-1209. 10.1021/bi048032c 15667213
27. Nolte RT Wisely GB Westin S Cobb JE Lambert MH Kurokawa R Rosenfeld MG Willson TM Glass CK Milburn MV Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma Nature 1998, 395(6698):137-143. 10.1038/25931 9744270
28. Cronet P Petersen JF Folmer R Blomberg N Sjoblom K Karlsson U Lindstedt EL Bamberg K Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family Structure 2001, 9(8):699-706. 10.1016/S0969-2126(01)00634-7 11587644
29. Bucher HC Hengstler P Schindler C Meier G N-3 polyunsaturated fatty acids in coronary heart disease: A meta-analysis of randomized controlled trials Am J Med 2002, 112(4):298-304. 10.1016/ S0002-9343(01)01114-7 11893369
30. Fortin PR Lew RA Liang MH Wright EA Beckett LA Chalmers TC Sperling RI Validation of a meta-analysis: The effects of fish oil in rheumatoid arthritis J Clin Epidemiol 1995, 48(11):1379-1390. 10.1016/ 0895-4356(95)00028-3 7490601
31. Morris MC Sacks F Rosner B Does fish oil lower blood pressure? A meta-analysis of controlled trials Circulation 1993, 88(2):523-533. 8339414
32. Sinn N Bryan J Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD J Dev Behav Pediatr 2007, 28(2):82-91. 10.1097/ 01.DBP.0000267558.88457.a5 17435458
33. Manco M Calvani M Mingrone G Effects of dietary fatty acids on insulin sensitivity and secretion Diabetes Obes Metab 2004, 6(6):402-413. 10.1111/j.1462-8902.2004.00356.x 15479216
34. Mustad VA Demichele S Huang YS Mika A Lubbers N Berthiaume N Polakowski J Zinker B Differential effects of n-3 polyunsaturated fatty acids on metabolic control and vascular reactivity in the type 2 diabetic ob/ob mouse Metabolism 2006, 55(10):1365-1374. 10.1016/j.metabol.2006.06.007 16979408
35. Podolin DA Gayles EC Wei Y Thresher JS Pagliassotti MJ Menhaden oil prevents but does not reverse sucrose-induced insulin resistance in rats Am J Physiol 1998, 274(3 Pt 2):R840-8. 9530253
36. Lin Q Ruuska SE Shaw NS Dong D Noy N Ligand selectivity of the peroxisome proliferator-activated receptor alpha Biochemistry (Mosc) 1999, 38(1):185-190. 10.1021/bi9816094 9890897
37. Hamilton JA Fatty acid transport: Difficult or easy? J Lipid Res 1998, 39(3):467-481. 9548581
38. Fyffe SA Alphey MS Buetow L Smith TK Ferguson MA Sorensen MD Bjorkling F Hunter WN Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids J Mol Biol 2006, 356(4):1005-1013. 10.1016/j.jmb.2005.12.047 16405912
39. Jiang C Ting AT Seed B PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 1998, 391(6662):82-86. 10.1038/ 34184 9422509
40. Ray DM Akbiyik F Bernstein SH Phipps RP CD40 engagement prevents peroxisome proliferator-activated receptor gamma agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-kappaB-dependent mechanism J Immunol 2005, 174(7):4060-4069. 15778364
41. Ricote M Li AC Willson TM Kelly CJ Glass CK The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation Nature 1998, 391(6662):79-82. 10.1038/34178 9422508
42. Piva R Gianferretti P Ciucci A Taulli R Belardo G Santoro MG 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: An effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins Blood 2005, 105(4):1750-1758. 10.1182/blood-2004-04-1360 15498850
43. Lo Verme J Fu J Astarita G La Rana G Russo R Calignano A Piomelli D The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide Mol Pharmacol 2005, 67(1):15-19. 10.1124/mol.104.006353 15465922
44. Grommes C Landreth GE Heneka MT Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists Lancet Oncol 2004, 5(7):419-429. 10.1016/S1470-2045(04)01509-8 15231248
45. Granlund L Larsen LN Nebb HI Pedersen JI Effects of structural changes of fatty acids on lipid accumulation in adipocytes and primary hepatocytes Biochim Biophys Acta 2005, 1687(1-3):23-30. 15708350